INTRODUCTION
Testicular cancer (TC) is the most common cancer among men aged 18 to 39 years, with increasing incidence over the past 20 years. 1 With cisplatin-based chemotherapy, patients with metastatic disease have achieved unprecedented survival rates, 2 with cure expected in 80%. 3 Overall, the 5-year relative survival rate for all TC patients is 95%. 4 As a result, 1 in 600 men in the U.S. is now a TC survivor (TCS), 5 with a gain of upwards of 40 years of life. 6 Thus, TCS comprise a unique population in which to study the long-term adverse effects of cancer treatment in adult-onset cancer survivors. 7 In particular, TCS given chemotherapy experience up to 7-fold increased long-term risks for cardiovascular disease (CVD) compared to controls. [8] [9] [10] [11] [12] [13] In the general population, metabolic syndrome (MetS) is a major risk factor for CVD. 14 MetS is a constellation of interrelated CVD risk factors, including insulinresistance, hypertension, elevated triglyceride levels, decreased high-density lipoprotein (HDL) levels, and obesity. 14 Using various definitions, European studies of TCS have reported a wide variation in the prevalence of MetS, ranging from 13%-39%. [15] [16] [17] [18] [19] Some investigations have demonstrated MetS risk to be higher among TCS compared to controls, [15] [16] [17] [18] but others have not. 19 Boer et al. 20 reported MetS to be more prevalent in TCS carrying the minor allele of a single nucleotide polymorphism (SNP), rs523349 (V89L), compared to wild type (33% vs. 19%, P=.032) . This SNP is a nonsynonymous coding variant in the gene SRD5A2, encoding steroid 5-α-reductase type II. The prevalence of MetS was particularly high (66.7%) in TCS who had low testosterone levels (<4.3 ng/mL) and carried a minor allele (homozygous or heterozygous) genotype.
Given the conflicting data on MetS prevalence in European studies of TCS and the lack of information in North American patients, we evaluated for the first time MetS and associated risk factors among a large cohort of North American TCS. 21 We also examined the reported association of the rs523349 SNP with MetS in our patients.
PATIENTS AND METHODS

Participants
The Platinum Study evaluates the late consequences of platinum-based chemotherapy and was approved by Institutional Review Boards at all participating institutions. 21, 22 Each participant provided written informed consent allowing access to medical records since cancer diagnosis. Eligibility criteria included: diagnosis of germ cell tumor (GCT) at age <55 years; treatment with first-line platinum-based chemotherapy, no salvage chemotherapy, no radiotherapy, and no antecedent chemotherapy for another primary cancer. All participants were disease-free at the time of clinical evaluation. We included in this analysis all TCS for whom blood samples had been analyzed and who had complete data on all MetS components.
Assessments
2.2.1 Socio-demographic, lifestyle, and behavioral factors. TCS completed a questionnaire regarding health outcomes, lifestyle behaviors and current prescription medications (including antihypertensive, diabetic and lipid-lowering medications).
Demographic information included age at cancer diagnosis and clinical evaluation, race, education, employment and marital status. Smoking status was categorized as current, former, or never smoker. Physical activity was reported as the average time per week engaged in various forms of exercise. 23 Moderate-and vigorous-intensity physical activity were defined as participating in at least one activity per week with a metabolic equivalent (MET) of 3 to <6 METs or ≥6 METs, respectively. 24,25
Data collection from medical records. Study staff abstracted data
according to a uniform protocol, using forms adapted from a prior study. 22 Data included date of GCT diagnosis, histology and site of GCT, and for each cytotoxic drug: name, dose, date(s) of administration, number of cycles, and cumulative dose. All data were entered into the eClinical system, 26 supported by the study coordinating center.
Clinical evaluation. TCS underwent a physical examination measuring
height, weight, and waist circumference. Body mass index (BMI) was calculated as kg/m 2 . Blood pressure was measured twice after resting for 5 minutes and averaged.
Blood samples were drawn and time of last meal was recorded. Blood samples were frozen and shipped to the central laboratory. Serum levels of testosterone, luteinizing hormone (LH), lipids, creatinine; and soluble cell adhesion molecule-1 (sICAM-1), a known CVD biomarker, 27-29 were measured using commercial assays. Hypogonadism was defined using the U.S. Food and Drug Administration definition (total serum testosterone ≤3.0 ng/mL), 30 which is commonly used in clinical practice. Integrative Medical Science (Yokohama, Japan). Because the SNP of interest is not called on this chip, we performed genotype imputation following standard quality control measures as previously described. 31 Imputation was performed on the University of Michigan Imputation Server 32 with the following parameters: 1000G Phase 1 v3 Shapet2 (no singletons) reference panel, SHAPEIT phasing, and the EUR (European) population. Linkage Disequilibrium (LD) structures around the variant of interest were determined using NIH's LDLink 33 using the CEU (European) population.
Definition of MetS
MetS was defined using a modification of the National Cholesterol Education Program's Adult Treatment Panel III (NCEP ATP III) Guidelines 14 as the presence of ≥3 of the following (Table 1) : 1) systolic blood pressure ≥130 mmHg and/or diastolic blood pressure ≥85 mmHg or use of antihypertensive medication; 2) abdominal obesity (waist circumference ≥102 cm); 3) self-reported diabetes and medication use; 4) HDL cholesterol <40 mg/dL or lipid-lowering medication; and 5) serum triglyceride level ≥150 mg/dL (fasting) or ≥175 mg/dL (non-fasting). These MetS critera were developed by several major organizations to represent one harmonized definition. 14 Criteria for HDL and triglyceride cut-points were adapted from recent guidelines. 34
Control group
Matched controls for selected comparisons were chosen from the National Health and Nutrition Examination Survey (NHANES) using two consecutive data sets (2011-2012 and 2013-2014) , following methods applied by the St. Jude's Lifetime Cohort. 35 Controls (restricted to men without cancer) were matched 1:1 on race, age (within 5-years), and educational level.
Statistical analyses
Data were summarized with median (ranges) for continuous variables and proportions for categorical variables in two TCS subgroups defined by the presence or absence of MetS. The two groups were compared using the Pearson chi-square and two-sided Wilcoxon Rank Sum tests on categorical and continuous variables, respectively. TCS were compared to controls using the Pearson chi-square test with regard to the prevalence of various MetS components, as well as other CVD risk factors not included in the NCEP ATP III criteria. A composite score was calculated based on the cut-points for the individual MetS components, with a range of 0-5; zero indicated no abnormal components. Based on MetS diagnostic criteria, 14 participants with a composite score of 3-5 were classified with MetS.
To determine factors associated with MetS in TCS, a two-step approach was used. First, logistic regression models were used to estimate the odds ratios (OR), 95% confidence intervals (CI) and P-values for all clinical, demographic, behavioral, and laboratory measures. Second, factors that were significantly associated with MetS in univariate analyses were included in the multivariable model. All statistical analyses were conducted using SAS version 9.4. All tests were two-sided, with P-values <.05 considered statistically significant.
RESULTS
TCS characteristics.
Median time from chemotherapy completion to study enrollment was 4.7 years (range=0.4-23.9 [41] [42] [43] [44] [45] have each been shown to induce CTI-MetS. In TCS, hypogonadism and chemotherapy rather than sedentary behavior are likely the main causes for metabolic abnormalities. Our TCS were at least twice more likely than controls to engage in moderate or vigorous-intensity physical activity. Despite this, we did not find a significant difference in the prevalence of MetS between TCS and NHANES controls, likely because MetS criteria originally developed for the general population 14 do not reflect the full spectrum of metabolic abnormalities seen in TCS.
The relationships between hypogonadism with MetS and CVD in the general population [46] [47] [48] [49] [50] [51] [16] [17] [18] [19] are well-established. In our study, about one third of survivors were hypogonadal, which is higher than reported in the general population, 52 but not unexpected since our participants had undergone orchiectomy. In our cohort, TCS with hypogonadism were twice as likely to have MetS in multivariate analysis.
Hypogonadism also correlated with obesity, hypertension, high LDL and total cholesterol in univariate analysis (data not shown). Hypogonadism may also explain the lower prevalence of low HDL in TCS compared to controls as androgens can have a suppressive effect on HDL. 53 In addition, the smaller waist circumference in TCS compared to controls while having a higher BMI may be explained by increased femoral adipose tissue deposition observed in hypogonadal compared with eugonadal patients. 54 Studies of the effect of testosterone replacement on MetS and CVD risk in TCS are sparse. While such investigations in older men in the general population showed favorable effects on lipid metabolism, bone mineral density, muscle mass, and fat-free body mass, 55,56 the effects of testosterone replacement on CVD risk have been conflicting. 57 One clinical trial showed an excess of CVD adverse events in older men treated with testosterone compared with placebo, 58 but another trial in a similar population did not. 59 However, these findings may not apply to young and physically active TCS. For young TCS with symptomatic hypogonadism, testosterone replacement should be considered, and future research is needed to address both the benefits and risks of testosterone replacement therapy.
Inflammation is considered a critical pathogenic component of atherosclerosis. 60 de Haas et al. provided a comprehensive assessment of pro-inflammatory markers in chemotherapy-treated TCS, finding significantly elevated levels of several markers in patients with MetS vs. those without MetS. 17 Herein, we found that sICAM levels increased with increasing MetS risk even after adjustment for age and additional risk factors in multivariate analysis. sICAM is an adhesion molecule that serves a critical role in the adhesion and transmigration of leucocytes across the endothelial wall, an early step in the formation of the atherosclerotic plaque. 61 Epidemiological studies have shown strong, positive associations between sICAM levels and future CVD events in apparently healthy men and women. 27-29 Vaughn et al. reported sICAM levels to be higher in TCS treated with chemotherapy than surgery only, suggesting a direct mechanism for CVD through chemotherapy-induced endothelial dysfunction. 62 In vitro studies further support this hypothesis. [63] [64] [65] There has been increasing interest in personalizing care for cancer survivors.
One approach is to identify genetic variants that can predispose survivors to selected adverse health outcomes. 7 In this study, we evaluated a SNP (rs523349) in the steroid 5-α-reductase type II gene recently associated with MetS in TCS. 20 This SNP decreases enzyme activity and thus the conversion of testosterone to the more active metabolite dihydrotestosterone. 66 The frequencies of the wild type and variant rs523349 in our cohort were comparable to those in Boer et al 20 (Table 7) ; however, in our cohort with more than twice the sample size, we found no association with MetS. An approach that accounts for multiple genes involved in relevant pathways may better identify clinically actionable results that could inform risk-adapted management approaches.
The prevalence of MetS in our patients is within the range (17%-41%) reported in European studies of platinum-treated TCS (summarized in vs. 14%). The association between cisplatin-based chemotherapy, hypertension, and CVD in TCS is well-established, and has been reviewed elsewhere. 7, 65 
Strengths and limitations:
Strengths of our study include the large number of patients, detailed medical chart abstraction, and use of contemporary and homogeneous platinum-based chemotherapy regimens. We used a definition for hypogonadism that is clinicallyrelevant and easily applicable to clinical practice. However, any cross-sectional design has potential limitations and does not allow us to infer causation of evaluated risk factors to MetS, although prospective data collection is planned for this cohort. Also, the SNP of interest was imputed and not genotyped, although it was in perfect LD with a nearby genotyped SNP. Our participants also represent for the most part well-educated TCS followed at major academic institutions and the prevalence of MetS may be higher in community-based settings.
Moreover, participants in the population-based NHANES cohort may not be comparable to our TCS in terms of all relevant sociodemographic and lifestyle variables.
Conclusion and recommendations:
There is a high prevalence of metabolic abnormalities in TCS treated with chemotherapy at a relatively young age and shortly after completion of cancer treatment. ¶ The non-white population consisted of 5 (1.0%) Black/African American; 18 (3.7%) Asian; 1 (0.2%) American Indian; 9 (1.9%) who identified more than one race; 24 (4.9%) other race; and 9 (1.9%) whose race was not stated. # Not married includes 157 (32.3%) TCS who were single, 30 (6.2%) survivors who were widowed/divorced/separated, and 8 (1.6%) who preferred not to disclose marital status. 3 (0.6) 0 (0.0) Abbreviations: BP = blood pressure; CVD = cardiovascular disease; LDL = low-density lipoprotein; MetS = metabolic syndrome; NHANES = National Health and Nutrition Examination Survey * Please refer to Methods for definition of MetS. Controls were 1:1 age-, race-and educational levelmatched males from the National Health and Nutrition Examination Survey (NHANES). † P-values obtained from Pearson chi-square test. ‡ Patients were asked if they had ever taken prescription medications for high cholesterol. These may have included statins, fibrates and/or nicotinic acid. § Cut-off points for elevated triglycerides are 150 mg/dL for those who had fasted for 8 hours or more and 175 mg/dL for those who had less than 8 hours of fasting prior to blood sample collection. 39 ǁ 25 participants in the NHANES cohort had missing data on LDL cholesterol.
¶ The vigorous-intensity and moderate-intensity physical activity groups are not mutually exclusive. There are a total of 9 different activities surveyed in the Platinum Study, some of which are moderate-intensity activities and some of which are vigorous-intensity activities. If a subject reported that he spent one hour walking a week (i.e. a moderate-intensity activity) and 30 minutes running per week (i.e. a vigorousintensity activity), he was included as a yes for both "any moderate" and "any vigorous" activity. 23, 24 Three survivors did not provide data on physical activity. n/a n/a n/a n/a n/a n/a Dyslipidemia (Low HDL or statin usage) n/a n/a n/a n/a n/a n/a n/a 35 (20.1) 7 (12.3) 36 (10.0) Elevated triglycerides n/a n/a n/a n/a n/a n/a 50 (29) 61 (35.1) 13 (22.8) 84 (23.3) Insulin resistance n/a n/a n/a n/a n/a n/a n/a 11 (6.3) 2 (3.5) 16 (4.4) Diabetes ¶ ¶ ¶ 11 (2.9) 2 (2.3) 4 (1.8) 33 (2.9) 5 (2.5) 2 (1.6%) n/a n/a n/a n/a Age-adjusted OR (95% CI) for MetS Survivors vs. healthy controls (1.3-3.4) n/a 1.0 n/a n/a n/a 2. (6.4-32.1) 16.8 (7.6-33.9 ) § § § § n/a 18.0 ; No MetS
